Conclusions: Patients treated with infliximab have greater adherence than patients treated with etanercept and adalimumab, with mode of administration most likely playing a fundamental role.
Ályktanir: Meðferðarheldni sjúklinga á infliximab er betri í samanburði við þá sem eru á etanercept og adalimumab.